Oculis Holding AG Ordinary shares OCS
i
Market datapartial · fetched 2026-11-04T03:38:54.914Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:11:33.713601455Z
FundamentalsAlpha Vantage · unavailable
Oculis Holding AG Ordinary shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.42 | 300.3% | 41.0% | |||
| 25Δ | 5.87 | 285.8% | 37.4% | |||
| 30Δ | 6.32 | 271.3% | 33.9% | |||
| 35Δ | 6.77 | 256.8% | 30.3% | |||
| 40Δ | 7.23 | 242.4% | 26.8% | |||
| 45Δ | 42.44 | 800.0% | 468.7% | 7.68 | 227.9% | 23.2% |
| 50Δ | 32.26 | 783.1% | 339.8% | 8.13 | 213.4% | 19.7% |
| 55Δ | 15.73 | 602.2% | 130.3% | 8.58 | 198.9% | 16.1% |
| 60Δ | 9.04 | 184.4% | 12.5% | |||
| 65Δ | 9.49 | 169.9% | 9.0% | |||
| 70Δ | 9.94 | 155.4% | 5.4% | |||
| 75Δ | 10.59 | 153.4% | 4.1% | |||
| 80Δ | 11.27 | 153.3% | 3.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.42
- IV
- 300.3%
- B/E move
- 41.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.87
- IV
- 285.8%
- B/E move
- 37.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.32
- IV
- 271.3%
- B/E move
- 33.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.77
- IV
- 256.8%
- B/E move
- 30.3%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.23
- IV
- 242.4%
- B/E move
- 26.8%
45Δ
- Pseudo strike
- 42.44
- IV
- 800.0%
- B/E move
- 468.7%
- Pseudo strike
- 7.68
- IV
- 227.9%
- B/E move
- 23.2%
50Δ
- Pseudo strike
- 32.26
- IV
- 783.1%
- B/E move
- 339.8%
- Pseudo strike
- 8.13
- IV
- 213.4%
- B/E move
- 19.7%
55Δ
- Pseudo strike
- 15.73
- IV
- 602.2%
- B/E move
- 130.3%
- Pseudo strike
- 8.58
- IV
- 198.9%
- B/E move
- 16.1%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.04
- IV
- 184.4%
- B/E move
- 12.5%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.49
- IV
- 169.9%
- B/E move
- 9.0%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.94
- IV
- 155.4%
- B/E move
- 5.4%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.59
- IV
- 153.4%
- B/E move
- 4.1%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.27
- IV
- 153.3%
- B/E move
- 3.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 215.27% | |
| 215.41% | |
| 213.67% | |
| 229.82% | |
| 230.46% |
Biotechnology
OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its…
More →OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company…
More →OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting…
More →ONC
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The…
More →ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San…
More →ORKA
Description unavailable
More →